Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Net Income	-91.34
Depreciation & Amortization	0.03
Loss (Gain) From Sale of Investments	-2.45
Stock-Based Compensation	16.28
Other Operating Activities	1.74
Change in Accounts Payable	10.35
Change in Other Net Operating Assets	2.3
Operating Cash Flow	-63.09
Capital Expenditures	-0.21
Investment in Securities	-359.93
Investing Cash Flow	-360.14
Total Debt Issued	27.25
Net Debt Issued (Repaid)	27.25
Issuance of Common Stock	454.57
Other Financing Activities	5.39
Financing Cash Flow	490.41
Net Cash Flow	67.17
Free Cash Flow	-63.3
Free Cash Flow Per Share	-3.77

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q